Acute myocardial infarction and increased soluble intercellular adhesion molecule-1: A marker of vascular inflammation and a risk of early restenosis?

American Heart Journal

Volumn 136, Issue 2, 1998, Pages 231-236

  Kamijikkoku, Shuichi ^b   Murohara, Toyoaki ^a   Tayama, Shinji ^b   Matsuyama, Kozaburou ^b   Honda, Takashi ^b   Ando, Masayuki ^b   Hayasaki, Kazuya ^b  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY OBSTRUCTION; CORONARY RISK; EMERGENCY TREATMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULITIS;

EID: 0031817773     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1053/hj.1998.v136.89407     Document Type: Article

References (38)

1. Nobuyoshi M, Kimura T, Nosaka H. Restenosis after successful percutaneous coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol 1988;12:616-23.
2. Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after arterial injury. Lab Invest 1983;49:208-15.
3. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest 1991;64:5-15.
4. Schwartz RS, Holmes DR, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992;20:1284-93.
5. Glagov S. Intimal hyperplasia, vascular modeling, and the restenosis problem. Circulation 1994;89:2888-92.
6. De Servi S, Mazzone A, Ricevuti G, Fioravanti A, Bramucci E, Angoli L, et al. Granulocyte activation after coronary angioplasty in humans. Circulation 1990;82:140-6.
7. Mehta J, Dinerman J, Mehta P, Saldeen TG, Lawson D, Donnelly WH, et al. Neutrophil function in ischemic heart disease. Circulation 1989;79:549-56.
8. Springer TA. Adhesion receptors of the immune system. Nature 1990;346:425-34.
9. Butcher EC. Leukocyte-endothelial cell adhesion recognition: three (or more) steps to specificity and diversity. Cell 1991;67:1033-6.
10. Marlin SD, Springer TA. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function associated antigen 1 (LFA-1). Cell 1987;51:813-9.
11. Meerschaert J, Furie MB. The adhesion molecules used by monocytes for migration across endothelium include CD 11a/CD18, CD11b/CD18, and VLA-4 on monocytes and ICAM-1, VCAM-1, and other ligands on endothelium. J Immunol 1995;154:4099-112.
12. Albelda SM, Muller WA, Buck CA, Newman PJ. Molecular and cellular properties of PECAM-1 (endoCAM/CD31): a novel vascular cell-cell adhesion molecule. J Cell Biol 1991;114:1059-68.
13. Szekanecz Z, Shah MR, Pearce WH, Koch AE. Intercellular adhesion molecule-1 (ICAM-1) expression and soluble ICAM-1 (sICAM-1) production by cytokine-activated human aortic endothelial cells: a possible role for ICAM-1 and sICAM-1 in atherosclerotic aortic aneurysms. Clin Exp Immunol 1994;98:337-43.
14. Hashimoto M, Shingu M, Ezaki l, Nobunaga M, Minamihara M, Kato K, et al. Production of soluble ICAM-1 from human endothelial cells induced by IL-1 beta and TNF-alpha. Inflammation 1994;18:163-73.
15. Couffinhal T, Duplaa C, Labat L, Lamaziere JM, Moreau C, Printseva O, et al. Tumor necrosis factor-alpha stimulates ICAM-1 expression in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1993;13:407-14.
16. Tanaka H, Sukhova GK, Swanson SJ, Clinton SK, Ganz P, Cybulsky MI, et al. Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury. Circulation 1993;88:1788-803.
17. Seth R, Raymond FD, Makgoba MW. Circulating ICAM-1 isoforms: diagnostic prospects for inflammatory and immune disorders. Lancet 1991;338:83-4.
18. Rothlein R, Mainolfi EA, Czajkowski M, Marlin SD. A form of circulating ICAM-1 in human serum. J Immunol 1991;147:3788-93.
19. Budnik A, Grewe M, Gyufko K, Krutmann J. Analysis of the production of soluble ICAM-1 molecules by human cells. Exp Hematol 1996;24:352-9.
20. Küster H, Degitz K. Circulating ICAM-1 in neonatal sepsis. N Engl J Med 1993;341:506.
21. Haught WH, Mansour M, Rothlein R, Kishimoto TK, Mainolfi EA, Hendricks JB, et al. Alterations in circulating intercellular adhesion molecule-1 and L-selectin: further evidence for chronic inflammation in ischemic heart disease. Am Heart J 1996;132:1-8.
22. Christiansen I, Gidlof C, Kalkner K-M, Hagberg H, Bennmarker H, Totterman T. Elevated serum levels of soluble ICAM-1 in non-Hodgkin's lymphomas correlate with rumour burden, disease activity and other prognostic markers. Br J Haematol 1996;92:639-46.
23. Altomonte M, Colizzi F, Esposito G, Maio M. Circulating intercellu-lar adhesion molecule 1 as a marker of disease progression in cutaneous melanoma. N Engl J Med 1992;327:959.
24. Boldt J, Wollbruck M, Kuhn D, Linke LC, Hempelmann G. Do plasma levels of circulating soluble adhesion molecules differ between surviving and nonsurviving critically ill patients? Chest 1995;107:787-92.
25. AHA Committee Report: a reporting system on patients evaluated for coronary artery disease. Circulation 1975;51:5-40.
26. Poston RN, Haskard DO, Coucher JR, Gall NP, Johnson-Tidey RR. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am J Pathol 1992;140:665-73.
27. Lowe GDO, Machado SG, Krol WF, Barton BA, Forbes CD. White blood cell count and haematocrit as predictors of coronary recurrence after myocardial infarction. Thromb Haemost 1985;54:700-3.
28. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis. A special case of atherosclerosis progression. Circulation 1992;86(Suppl 6):III47-52.
29. Clausell N, de Lima VC, Molossi S, Liu P, Turley E, Gotlieb AI, et al. Expression of tumor necrosis factor alpha and accumulation of fibronectin in coronary artery restenotic lesions retrieved by atherectomy. Br Heart J 1995;73:534-9.
30. Kling D, Fingerle J, Harlan JM. Inhibition of leukocyte extravasation with a monoclonal antibody to CD18 during formation of experimental intimal thickening in rabbit carotid arteries. Arterioscler Thomb Vasc Biol 1992;12:997-1007.
31. Yasukawa H, Imaizumi T, Matsuoka H, Nakashima A, Morimatsu M. Inhibition of intimal hyperplasia after balloon injury by antibodies to intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1. Circulation 1997;95:1515-22.
32. Nageh MF, Sandberg ET, Marotti KR, Lin AH, Melchior EP, Bullard DC, et al. Deficiency of cell adhesion molecules protects against atherosclerosis in mice [abstract]. J Am Coll Cardiol 1997;29(Suppl A);153A.
33. Hwang S-J, Ballantyne CM, Sharret AR, Smith LC, Davis CE, Gotto AM Jr, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. The atherosclerosis risk in communities (ARIC) study. Circulation 1997;96:4219-25.
34. Youker KA, Hawkins HK, Kukielka GL, Perrard JL, Michael LH, Ballantyne CM, et al. Molecular evidence for induction of intercellular adhesion molecule-1 in the viable border zone associated with ischemia-reperfusion injury of the dog heart. Circulation 1994;89:2736-46.
35. Barnett CC Jr, Moore EE, Moore FA, Carl VS, Biffl WL. Soluble ICAM-1 (sICAM-1) provokes PMN elastase release. J Surg Res 1996;63:6-10.
36. Tsutsui M, Shimokawa H, Tanaka S, Yoshihara S, Higuchi S, Matsuguchi T, et al. Granulocyte activation in restenosis after percutaneous transluminal coronary angioplasty. Jpn Circ J 1996;60:27-34.
37. Meyer DM, Dustin ML, Carron CP. Characterization of intercellular adhesion molecule-1 ectodomain (sICAM-1) as an inhibitor of lymphocyte function-associated molecule-1 interaction with ICAM-1. J Immunol 1995;155:3578-84.
38. Reilly PL, Woska JR Jr, Jeanfavre DD, McNally E, Rothlein R, Bormann B-J. The native structure of intercellular adhesion molecule-1 (ICAM-1) is a dimer. Correlation with binding to LFA-1. J Immunol 1995;155:529-32.